Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;35(6):e15482.
doi: 10.1111/dth.15482. Epub 2022 Apr 11.

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study

Cosimo Di Raimondo  1   2 , Sara Vaccarini  3 , Andrea Nunzi  3 , Vito Rapisarda  3 , Annagiulia Zizzari  3 , Federico Meconi  3 , Alessandro Monopoli  2 , Maria Grazia Narducci  2 , Enrico Scala  2 , Luca Bianchi  1 , Cristiano Tesei  3 , Maria Cantonetti  3
Affiliations

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study

Cosimo Di Raimondo et al. Dermatol Ther. 2022 Jun.

Abstract

The aim of our retrospective study was to evaluate the efficacy of a continuous therapy with a lower dosage of gemcitabine compared to those usually administered in patients with cutaneous T cell lymphomas (CTCL). Twenty-two patients received different dosages of gemcitabine. Dosage and schedule of the drug were chosen on the basis of clinical features. Gemcitabine was given at 1000 mg every 15 days in 13 patients (four mycosis fungoides [MF], nine Sezary syndrome [SS]); at 1000 mg at days +1, +8, +15 in six cases (three MF, three SS). All patients had been previously treated: four patients had received both skin directed and systemic treatments. Eighteen patients had received photopheresis, IFN, chemotherapy and immunotherapy. The objective response rate (CR + PR) among all patients was 54.5% (12 of 22 patients) with a CR of 4.5% (one of 22 patients) and a PR of 50% (11 of 22 patients). Patients with SS had an ORR of 61.5% (eight of 13 patients) with one CR (7%) and seven PR (53.8%); patients with MF showed an ORR of 55.6% (five of nine patients) but no patients experienced CR (0%). The schedule with the highest efficacy and the lowest toxicity profile was 1000 mg every 15 days. Median progression free survival and overall survival in all patients were 17 and 45 months respectively. Gemcitabine was generally well tolerated. We have demonstrated that a much lower dose of gemcitabine (1000 mg once every 15 days) in patients with advanced-stage and refractory CTCL can lead to a durable response, with tolerable and manageable adverse effects.

Keywords: Sezary syndrome; cutaneous T cell lymphoma; cutaneous malignancies; gemcitabine; mycosis fungoides.

PubMed Disclaimer

References

REFERENCES

    1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
    1. Martinez XU, di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: erythrodermic mycosis fungoides and Sezary syndrome. Best Pract Res Clin Haematol. 2019;32(3):239-252.
    1. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
    1. Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas-an update 2019. Hematol Oncol. 2019;37(Suppl. 1):43-47.
    1. Quaglino P, Fava P, Pileri A, et al. Phenotypical markers, molecular mutations, and immune microenvironment as targets for new treatments in patients with mycosis fungoides and/or Sezary syndrome. J Invest Dermatol. 2020;141(3):484-495.

MeSH terms